{"entity":{"id":"nct06885840","kind":"trial","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","aka":[],"tldr":"A phase 2 trial of MCLA-129 in lung cancer, run by Betta Pharmaceuticals Co., Ltd., not yet recruiting.","summary":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. is a phase 2, interventional study registered as NCT06885840 by Betta Pharmaceuticals Co., Ltd., with a registry enrolment figure of 100 participants, started 2025-03-31 and due to reach its primary completion in 2028-04. Interventions recorded: MCLA-129. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Overall Response Rate (ORR). Lung eligibility wording from the registry: \"* Subjects must have histologically or cytologically confirmed locally advanced unresectable or metastatic NSCLC\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06885840","url":"https://clinicaltrials.gov/study/NCT06885840"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","met-altered-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["mcla-129"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06885840","phase":"2","setting":"A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.","sponsor":"Betta Pharmaceuticals Co., Ltd.","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06885840/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"}],"drug":[{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}